Home » Information and Communications Technology » Technology & Media » U.S. 3D Bioprinting Market

U.S. 3D Bioprinting Market

U.S. 3D Bioprinting Market By Material (Living Cells, Hydrogels, Extracellular Matrices, Other Material); By Application (Medical, Dental, Biosensors, Consumer/Personal Product Testing, Bioinks); By End-User (Academic & Research Institute, Pharmaceutical and Biotechnology Companies, Hospitals); By Technology (Inkjet-based, Magnetic Levitation, Syringe-based, Laser-based, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
U.S. 3D bioprinting Market Size 2023	USD 437.36 million
U.S. 3D bioprinting Market, CAGR	12.51%
U.S. 3D bioprinting Market Size 2032	USD 1,263.24 million

Market Overview:

U.S. 3D bioprinting Market size was valued at USD 437.36 million in 2023 and is anticipated to reach USD 1,263.24 million by 2032, at a CAGR of 12.51% during the forecast period (2023-2032).

Several key factors are propelling the growth of the 3D bioprinting market in the United States. The increasing prevalence of chronic diseases and an aging population are driving the need for innovative medical solutions. Additionally, the shortage of organ donors has intensified interest in tissue engineering and regenerative medicine. Technological advancements in bioprinting, such as improved bioinks and printing precision, are enhancing the viability and functionality of printed tissues and organs. Moreover, substantial investments in research and development by both public and private sectors are accelerating innovation and application of 3D bioprinting technologies. Furthermore, the growing focus on personalized medicine and the potential for customized treatments are further fueling market expansion.

The United States stands at the forefront of the global 3D bioprinting market, accounting for a significant share of the market revenue. This leadership is attributed to the country’s advanced healthcare infrastructure, substantial R&D investments, and the presence of leading bioprinting companies. The convergence of academic institutions, research organizations, and industry players fosters a collaborative environment conducive to technological advancements. Furthermore, favorable regulatory frameworks and funding mechanisms support the commercialization and adoption of 3D bioprinting solutions across various medical applications. The U.S. government’s increasing support for innovation in bioprinting technologies, coupled with the region’s expertise in biomedical engineering, reinforces its dominance in the market.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights:

The U.S. 3D bioprinting market was valued at USD 437.36 million in 2023 and is projected to reach USD 1,263.24 million by 2032, growing at a CAGR of 12.51%.

The global 3D bioprinting market was valued at USD 1,500.00 million in 2023 and is projected to reach USD 4,295.25 million by 2032, growing at a CAGR of 12.4% during the forecast period (2023-2032).

The increasing prevalence of chronic diseases, such as diabetes and cardiovascular diseases, is driving demand for advanced medical solutions, with bioprinting offering a way to create complex tissues for treatment and research.
Continuous technological advancements in bioprinting, including the development of improved bioinks and more precise printing techniques, are enhancing the viability and functionality of printed tissues and organs.
The shortage of organ donors in the U.S. is intensifying interest in bioprinting as a solution for tissue engineering and organ replacement, offering potential for addressing the organ transplant gap.
The U.S. government’s supportive regulatory environment and funding initiatives are accelerating the development and commercialization of bioprinting technologies, fostering innovation and collaboration in the sector.
Despite the potential, high costs of bioprinting systems and materials remain a significant barrier to widespread adoption, particularly for smaller healthcare institutions and research labs.
Regulatory and ethical concerns, along with the technical challenges of creating fully functional organs, are limiting the immediate potential of 3D bioprinting in clinical applications, though advancements continue to address these obstacles.

Report scope

This report segments the U.S. 3D bioprinting Market as follow:

Market Drivers:

Increasing Healthcare Needs and Chronic Disease Prevalence

The increasing prevalence of chronic diseases in the U.S. is one of the primary drivers of the 3D bioprinting market. Conditions such as cardiovascular diseases, diabetes, and cancer continue to rise, creating a demand for more advanced and personalized healthcare solutions. For instance, the University of Texas at El Paso (UTEP) received a $1.2 million grant from the National Institutes of Health (NIH) to use 3D bioprinting for modeling diabetes-related heart problems, specifically studying how type 2 diabetes affects cardiac tissue function and drug response. Bioprinting offers the potential to revolutionize the way these diseases are treated, enabling the creation of complex tissues that could be used for disease modeling, drug testing, and even personalized treatment strategies. This growing healthcare need supports the advancement of 3D bioprinting technologies, fueling their adoption in medical research and clinical applications.

Technological Advancements in Bioprinting

Another key driver for the U.S. 3D bioprinting market is the continuous technological advancements in bioprinting technologies. For example, volumetric bioprinting and microfluidic-based techniques now allow for the creation of tissue constructs with resolutions down to tens of micrometers, closely mimicking the finest features of human tissue microarchitecture. Significant improvements in the precision and resolution of bioprinting techniques have made it possible to print more complex tissue structures with better functionality. The development of advanced bioinks—materials that can mimic the properties of human cells and tissues—has also enhanced the viability of printed tissues for medical applications. These advancements are not only improving the quality of printed tissues and organs but also expanding the potential applications of bioprinting in regenerative medicine, drug development, and organ transplantation.

Shortage of Organ Donors

The shortage of organ donors remains a significant challenge in the U.S. healthcare system, driving demand for alternative solutions like 3D bioprinting. The National Organ Transplant Act (NOTA) has long recognized the need for more organ donations, but the number of available organs continues to fall short of demand. 3D bioprinting offers a promising solution by enabling the printing of functional tissues and organs that could one day help address the shortage. Although it is still in the early stages of development, the ability to print organs for transplantation or create tissue for regenerative treatments holds the potential to transform the field of medicine and alleviate the burden on the organ transplant system.

Supportive Regulatory Environment and Government Initiatives

The U.S. government’s supportive regulatory environment and funding initiatives are essential drivers of the 3D bioprinting market. Agencies such as the U.S. Food and Drug Administration (FDA) are working closely with bioprinting companies to establish clear guidelines for the development and approval of bioprinted tissues and organs. In addition, federal funding for bioprinting research and development is increasing, supporting innovation in this field. The growing recognition of bioprinting’s potential by regulatory bodies and policymakers has paved the way for advancements in bioprinting technologies, providing the market with the necessary resources and frameworks to flourish. Government initiatives also encourage public-private partnerships, fostering collaboration between research institutions, universities, and industry players to accelerate the commercialization of bioprinting applications.

Market Trends:

Expansion in Bioprinting Applications

One of the most significant trends driving the U.S. 3D bioprinting market is the expansion of its applications across various medical fields. While initially limited to research and academic institutions, 3D bioprinting is now being explored in a wide range of medical applications, from drug discovery and testing to tissue regeneration and personalized medicine. Increasingly, bioprinting is being used to create patient-specific models, which can be utilized in preclinical trials and surgical planning. As the technology matures, its potential to revolutionize medical treatments continues to grow, with more hospitals and pharmaceutical companies investing in 3D bioprinting to enhance healthcare outcomes.

Rise of Personalized Medicine

Personalized medicine is another growing trend in the U.S. 3D bioprinting market. There is a significant shift toward treatments tailored to individual genetic profiles, which is made possible by advances in 3D bioprinting. The ability to print tissues or organ structures based on a patient’s specific needs allows for more targeted therapies and reduced risks of rejection or complications. For instance, Brinter has developed modular 3D printing platforms that print patient-specific tumor models, allowing for personalized drug testing in cancer treatment. Personalized bioprinted tissues also enable more accurate testing of drugs on human-like tissues, leading to better drug efficacy and safety profiles. This trend is expected to increase demand for bioprinting solutions, particularly in the fields of cancer treatment, regenerative medicine, and genetic therapies.

Technological Integration with Other Innovations

The integration of 3D bioprinting with other cutting-edge technologies is a key trend within the U.S. market. These integrations include the use of artificial intelligence (AI), machine learning, and robotics to optimize printing precision and enhance the creation of functional tissue structures. AI is being employed to design and simulate complex tissue architectures, improving the overall quality and functionality of bioprinted tissues. For example, AI-driven generative design is helping companies like Prellis Biologics create vascularized tissue models for drug discovery, improving tissue viability by optimizing nutrient and oxygen delivery. Robotics are being used to automate the printing process, ensuring higher throughput and precision, which is crucial for clinical applications. These innovations are driving the development of bioprinting technologies, making them more efficient, scalable, and adaptable to various medical needs.

Growth of Public-Private Partnerships and Funding

Another important trend in the U.S. 3D bioprinting market is the increasing involvement of public-private partnerships and the growth of investment in this sector. Federal agencies such as the National Institutes of Health (NIH) and the Department of Defense (DoD) are providing funding to support the development of bioprinting technologies, particularly for applications in tissue engineering and organ regeneration. Additionally, venture capital and private equity investment are on the rise, as both large pharmaceutical companies and startup ventures recognize the long-term potential of 3D bioprinting. This trend of collaboration and investment is accelerating the pace of innovation and commercialization, driving further growth in the market.

Market Challenges Analysis:

High Costs of Technology and Implementation

One of the primary restraints in the U.S. 3D bioprinting market is the high cost associated with the technology and its implementation. Bioprinting systems, materials such as bioinks, and specialized equipment required for creating tissues and organs are expensive, which limits accessibility, especially for smaller research institutions and healthcare providers. Additionally, the complexity of maintaining and operating these systems increases operational costs, making widespread adoption a challenge. The high upfront investment required for both developing and implementing these technologies can delay the scalability of bioprinting solutions in clinical settings.

Regulatory and Ethical Concerns

Regulatory hurdles and ethical concerns also pose significant challenges to the growth of the U.S. 3D bioprinting market. The approval process for bioprinted tissues and organs is still in its infancy, with agencies like the U.S. Food and Drug Administration (FDA) working to establish clear guidelines. This lack of standardized regulations creates uncertainty for companies operating in the space. For instance, the FDA’s draft framework does not yet specify how regulations will be applied to point-of-care 3D printing facilities or clarify the risk classification of bioprinted products. Ethical concerns surrounding the creation of human tissues and organs, particularly with regard to potential misuse or unintended consequences, further complicate the development and adoption of 3D bioprinting technologies. These issues need to be addressed before bioprinting can fully realize its potential in healthcare.

Technical Limitations in Bioprinting Complexity

Despite advancements, the complexity of printing fully functional organs remains a significant challenge. Current bioprinting technologies are limited by their ability to accurately replicate the intricate structures and functionalities of human tissues and organs. While improvements in bioinks and printing techniques have enabled the production of simpler tissues, the ability to print complex, vascularized organs that can fully integrate with the human body is still an ongoing challenge. Until these technical limitations are overcome, the application of 3D bioprinting in organ transplantation and advanced regenerative medicine will remain limited.

Market Opportunities:

The U.S. 3D bioprinting market presents significant opportunities driven by the growing demand for personalized medicine and tissue engineering. The ability to create patient-specific models for drug testing, disease modeling, and personalized treatments provides a substantial market opportunity. As the technology advances, it can potentially eliminate the need for animal testing by offering more accurate human tissue models for research. This is particularly important for pharmaceutical companies, as it enables the development of more effective drugs with fewer side effects. Additionally, the growing shift toward regenerative medicine and organ transplantation opens doors for bioprinting technologies to create complex tissue structures for transplants, which could address the ongoing organ donor shortage.

Another promising opportunity lies in the collaboration between healthcare providers, research institutions, and biotechnology companies. With the increasing investments in research and development from both the public and private sectors, there is a clear path for the commercialization of 3D bioprinting solutions. Additionally, advancements in bioinks and printing techniques are paving the way for more complex and functional tissues, thereby expanding the scope of bioprinting applications in fields such as oncology, cardiovascular diseases, and neurological disorders. As healthcare providers seek innovative ways to deliver better outcomes, the adoption of 3D bioprinting as a tool for creating customized medical solutions is expected to increase significantly, fostering new market growth and opportunities for innovation.

Market Segmentation Analysis:

The U.S. 3D bioprinting market is segmented based on material, application, end-user, and technology, each contributing to the growth and expansion of the market.

By Material

The material segment is led by living cells, hydrogels, and extracellular matrices, all of which are integral to creating functional tissues and organs. Living cells are critical for replicating human tissues, while hydrogels provide a supportive environment for cell growth and extracellular matrices help mimic the natural biological scaffolding of tissues. Other materials include biocompatible polymers and composite materials, used for structural and functional support in bioprinting. These materials are essential in applications such as regenerative medicine and drug development.

By Application

The applications of 3D bioprinting span across medical, dental, biosensors, consumer/personal product testing, and bioinks. The medical sector remains the dominant application, with 3D bioprinting being used for tissue engineering, organ modeling, and drug testing. In the dental field, bioprinting is employed for creating customized implants and prosthetics. The use of bioprinting in biosensors and consumer products is growing, with companies leveraging the technology for product testing and development. Bioinks, a vital component for bioprinting, are also an emerging application as they enhance tissue and organ printing capabilities.

By End-User

End-users in the U.S. 3D bioprinting market include academic & research institutes, pharmaceutical and biotechnology companies, and hospitals. Academic institutions drive innovation through research, while pharmaceutical companies adopt bioprinting technologies for drug discovery and personalized treatments. Hospitals are exploring bioprinting for patient-specific treatments and organ modeling.

By Technology

The technology segment includes inkjet-based, magnetic levitation, syringe-based, and laser-based bioprinting. Inkjet-based technology is widely used due to its ability to print precise layers of materials, while syringe-based and laser-based technologies offer more control over the printing process. Magnetic levitation techniques are an emerging trend, offering the potential to create complex tissue structures without the need for scaffolding.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Segmentation:

By Material:

Living Cells
Hydrogels
Extracellular Matrices
Other Material

By Application:

Medical
Dental
Biosensors
Consumer/Personal Product Testing
Bioinks

By End-User:

Academic & Research Institute
Pharmaceutical and Biotechnology Companies
Hospitals

By Technology:

Inkjet-based
Magnetic Levitation
Syringe-based
Laser-based
Others

Regional Analysis:

The U.S. 3D bioprinting market is primarily driven by strong technological advancements, substantial healthcare investments, and a robust research ecosystem. The regional landscape is characterized by distinct contributions from different states and institutions, which collectively shape the growth of the market.

Northeast Region

The Northeast region, particularly states like Massachusetts, New York, and Pennsylvania, holds a significant share of the U.S. 3D bioprinting market, accounting for approximately 35% of the total market share. This is primarily due to the presence of world-renowned academic institutions and research hubs such as Harvard University, MIT, and major pharmaceutical companies like Pfizer. The region’s focus on biotechnology and medical research, along with strong government funding, fosters the development of 3D bioprinting technologies, especially in the fields of tissue engineering, drug testing, and personalized medicine. Additionally, the concentration of venture capital investment in the Northeast accelerates the commercialization of bioprinting solutions.

West Coast Region

The West Coast, particularly California, Oregon, and Washington, is another major contributor to the U.S. 3D bioprinting market, accounting for approximately 30% of the market share. The region is home to a thriving biotechnology industry, driven by leading companies such as Organovo, which has pioneered 3D bioprinting in medical research. California’s extensive healthcare infrastructure and strong support for research and development in regenerative medicine make it a vital hub for 3D bioprinting innovation. The West Coast also benefits from collaboration between tech giants and bioprinting startups, integrating artificial intelligence (AI) and machine learning with bioprinting technologies.

Midwest and South Regions

The Midwest and South regions hold smaller but significant shares of the U.S. 3D bioprinting market, accounting for approximately 20% and 15%, respectively. The Midwest, with major medical centers like the Mayo Clinic in Minnesota, has strong growth potential in the field of medical applications, particularly in personalized medicine and organ modeling. The South, including Texas, Florida, and Georgia, sees steady growth driven by healthcare and biotechnology firms, as well as research institutions focusing on medical device manufacturing and tissue engineering. Additionally, Texas is home to several bioprinting startups, fueling regional innovation.

Key Player Analysis:

Envisiontec, Inc
Organovo
Inventia Life Science Pty Ltd
POIETIS
VIVAX BIO, LLC
ALLEVI
Cyfuse Biomedical K.K.
3D Bioprinting Solutions
CELLINK GLOBAL
REGEMAT 3D S.L

Competitive Analysis:

The U.S. 3D bioprinting market is highly competitive, with several key players leading technological innovation and market adoption. Prominent companies like Organovo, 3D Systems, and Stratasys are at the forefront, offering advanced bioprinting platforms for medical research, drug development, and tissue engineering. Organovo is known for its pioneering work in creating functional human tissues, while 3D Systems and Stratasys have established themselves with versatile 3D printing solutions applicable across various industries, including healthcare. Additionally, startups such as BioBots and Allevi are gaining attention with their cost-effective and accessible 3D bioprinting solutions, enabling smaller research labs and academic institutions to adopt the technology. These companies are heavily investing in research and development to enhance the accuracy, scalability, and functionality of bioprinted tissues and organs. The competitive landscape is further shaped by partnerships, collaborations, and increasing venture capital funding, accelerating technological advancements and market growth.

Recent Developments:

In March 2025, CELLINK, a leading US-based 3D bioprinting company and part of BICO Group, announced a strategic partnership with DKSH to expand access to its advanced bioprinting solutions in China. This collaboration leverages DKSH’s extensive sales and service network to strengthen CELLINK’s market presence and accelerate biomedical research in the region, reflecting the company’s ongoing commitment to global expansion and innovation in 3D bioprinting.
In June 2024, Tethon 3D, a US developer specializing in ceramic and metal-polymer products, launched its first bioprinter, the Bison Bio DLP 3D bioprinter. Developed in collaboration with Carima, this new product features adjustable build sizes and compatibility with proprietary bioinks, positioning it to facilitate the creation of complex tissues and organs for biomedical research and personalized medicine. The Bison Bio aims to support advancements in healthcare by enabling more precise and efficient bioprinting processes.

Market Concentration & Characteristics:

The U.S. 3D bioprinting market is characterized by moderate concentration, with a few dominant players holding significant market shares while several emerging companies are driving innovation. Established leaders like Organovo, 3D Systems, and Stratasys hold a substantial portion of the market due to their advanced technologies, extensive patents, and strategic partnerships with academic institutions and research organizations. These companies focus on high-end, specialized bioprinting solutions for medical applications such as tissue engineering and regenerative medicine. At the same time, the market is becoming increasingly dynamic, with a growing number of startups such as Allevi and BioBots offering more affordable and accessible bioprinting solutions. This trend is expanding market access to smaller research labs and academic institutions, promoting greater diversity in product offerings. The market is characterized by ongoing technological advancements, regulatory uncertainties, and an increasing focus on collaborations and strategic alliances.

Report Coverage:

The research report offers an in-depth analysis based on Material, Application, End-User and Technology. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

The U.S. 3D bioprinting market is expected to see continued strong growth, driven by advancements in bioprinting technologies and increasing healthcare applications.
Personalized medicine will play a pivotal role, with 3D bioprinting enabling customized treatments for individual patients.
The demand for regenerative medicine and organ transplantation will increase as bioprinting technologies improve tissue and organ creation capabilities.
Investment in research and development by both private companies and government agencies will accelerate the pace of innovation.
Collaborations between biotech firms, research institutions, and universities will foster breakthroughs in 3D bioprinting applications.
The regulatory environment will gradually become clearer, enabling faster commercialization of bioprinted medical solutions.
Cost reduction in bioprinting materials and equipment will make the technology more accessible to a broader range of medical professionals and researchers.
Adoption of AI and machine learning in bioprinting processes will enhance precision and speed in tissue creation.
Startups and smaller firms will drive competition, offering innovative and cost-effective solutions to expand market reach.
Over the next decade, the 3D bioprinting market in the U.S. will become increasingly integrated into mainstream healthcare, especially in drug testing and personalized therapies.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. 3D BIOPRINTING Market Snapshot 21

2.1.1. United States 3D BIOPRINTING Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : 3D BIOPRINTING MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by United States 32

5.1.1. United States 3D BIOPRINTING Market Import Volume/Revenue, By United States, 2018 – 2023 32

5.2. Export Analysis by United States 33

5.2.1. United States 3D BIOPRINTING Market Export Volume/Revenue, By United States, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by United States 34

6.1.1. United States 3D BIOPRINTING Market Demand Volume/Revenue, By United States, 2018 – 2023 34

6.2. Supply Analysis by United States 35

6.2.1. United States 3D BIOPRINTING Market Supply Volume/Revenue, By United States, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by United States 36

7.1.1. United States 3D BIOPRINTING Market Production Volume/Revenue, By United States, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Material 37

8.1.1. United States 3D BIOPRINTING Market Price, By Material, 2018 – 2023 37

8.1.2. United States Material Market Price, By Material, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. United States 3D BIOPRINTING Market: Company Market Share, by Volume, 2023 40

11.1.2. United States 3D BIOPRINTING Market: Company Market Share, by Revenue, 2023 41

11.1.3. United States 3D BIOPRINTING Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. United States 3D BIOPRINTING Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. United States 3D BIOPRINTING Market Company Volume Market Share, 2023 43

11.3. United States 3D BIOPRINTING Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

United States Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : 3D BIOPRINTING MARKET – BY MATERIAL SEGMENT ANALYSIS 49

13.1. 3D BIOPRINTING Market Overview, by Material Segment 49

13.1.1. 3D BIOPRINTING Market Revenue Share, By Material, 2023 & 2032 50

13.1.2. 3D BIOPRINTING Market Attractiveness Analysis, By Material 51

13.1.3. Incremental Revenue Growth Opportunity, by Material, 2024 – 2032 51

13.1.4. 3D BIOPRINTING Market Revenue, By Material, 2018, 2023, 2027 & 2032 52

13.2. Living Cells 53

13.3. Hydrogels 54

13.4. Extracellular Matrices 55

13.5. Other Material 56

13.6. Material 5 57

CHAPTER NO. 14 : 3D BIOPRINTING MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. 3D BIOPRINTING Market Overview, by Application Segment 58

14.1.1. 3D BIOPRINTING Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. 3D BIOPRINTING Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. 3D BIOPRINTING Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Medical 62

14.3. Dental 63

14.4. Biosensors 64

14.5. Consumer/Personal Product Testing 65

14.6. Application 5 66

CHAPTER NO. 15 : 3D BIOPRINTING MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. 3D BIOPRINTING Market Overview, by End-user Segment 67

15.1.1. 3D BIOPRINTING Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. 3D BIOPRINTING Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. 3D BIOPRINTING Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Academic & Research Institute 71

15.3. Pharmaceutical and Biotechnology companies 72

15.4. Hospitals 73

15.5. End-user 4 74

15.6. End-user 5 75

CHAPTER NO. 16 : 3D BIOPRINTING MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. 3D BIOPRINTING Market Overview, by Technology Segment 76

16.1.1. 3D BIOPRINTING Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. 3D BIOPRINTING Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. 3D BIOPRINTING Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Inkjet-based 80

16.3. Magnetic Levitation 81

16.4. Syringe-based 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. 3D BIOPRINTING Market Overview, by Distribution Channel Segment 83

17.1.1. 3D BIOPRINTING Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. 3D BIOPRINTING Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. 3D BIOPRINTING Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Distribution Channel 1 87

17.3. Distribution Channel 2 88

17.4. Distribution Channel 3 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : 3D BIOPRINTING MARKET – UNITED STATES ANALYSIS 92

18.1. Material 92

18.1.1. United States 3D BIOPRINTING Market Revenue, By Material, 2018 – 2023 (USD Million) 92

18.2. United States 3D BIOPRINTING Market Revenue, By Material, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. United States 3D BIOPRINTING Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. United States 3D BIOPRINTING Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. United States 3D BIOPRINTING Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. United States 3D BIOPRINTING Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. United States 3D BIOPRINTING Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. United States 3D BIOPRINTING Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. United States 3D BIOPRINTING Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. United States 3D BIOPRINTING Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Envisiontec, Inc 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. Organovo 99

19.1.7. Inventia Life Science Pty Ltd 99

19.1.8. POIETIS 99

19.1.9. VIVAX BIO, LLC 99

19.1.10. ALLEVI 99

19.1.11. Cyfuse Biomedical K.K. 99

19.1.12. 3D Bioprinting Solutions 99

19.1.13. CELLINK GLOBAL 99

19.1.14. REGEMAT 3D S.L 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. United States 3D BIOPRINTING Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for United States 3D BIOPRINTING Market 29

FIG NO. 3. Value Chain Analysis for United States 3D BIOPRINTING Market 30

FIG NO. 4. United States 3D BIOPRINTING Market Import Volume/Revenue, By United States, 2018 – 2023 32

FIG NO. 5. United States 3D BIOPRINTING Market Export Volume/Revenue, By United States, 2018 – 2023 33

FIG NO. 6. United States 3D BIOPRINTING Market Demand Volume/Revenue, By United States, 2018 – 2023 34

FIG NO. 7. United States 3D BIOPRINTING Market Supply Volume/Revenue, By United States, 2018 – 2023 35

FIG NO. 8. United States 3D BIOPRINTING Market Production Volume/Revenue, By United States, 2018 – 2023 36

FIG NO. 9. United States 3D BIOPRINTING Market Price, By Material, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. 3D BIOPRINTING Market – Company Volume Market Share, 2023 43

FIG NO. 18. 3D BIOPRINTING Market – Company Revenue Market Share, 2023 44

FIG NO. 19. 3D BIOPRINTING Market Revenue Share, By Material, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Material 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Material, 2024 – 2032 51

FIG NO. 22. 3D BIOPRINTING Market Revenue, By Material, 2018, 2023, 2027 & 2032 52

FIG NO. 23. United States 3D BIOPRINTING Market for Living Cells, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. United States 3D BIOPRINTING Market for Hydrogels, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. United States 3D BIOPRINTING Market for Extracellular Matrices, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. United States 3D BIOPRINTING Market for Other Material, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. United States 3D BIOPRINTING Market for Material 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. 3D BIOPRINTING Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. 3D BIOPRINTING Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. United States 3D BIOPRINTING Market for Medical, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. United States 3D BIOPRINTING Market for Dental, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. United States 3D BIOPRINTING Market for Biosensors, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. United States 3D BIOPRINTING Market for Consumer/Personal Product Testing, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. United States 3D BIOPRINTING Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. 3D BIOPRINTING Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. 3D BIOPRINTING Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. United States 3D BIOPRINTING Market for Academic & Research Institute , Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. United States 3D BIOPRINTING Market for Pharmaceutical and Biotechnology companies, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. United States 3D BIOPRINTING Market for Hospitals, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. United States 3D BIOPRINTING Market for End-user 4, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. United States 3D BIOPRINTING Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. 3D BIOPRINTING Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. 3D BIOPRINTING Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. United States 3D BIOPRINTING Market for Inkjet-based, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. United States 3D BIOPRINTING Market for Magnetic Levitation, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. United States 3D BIOPRINTING Market for Syringe-based, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. 3D BIOPRINTING Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. 3D BIOPRINTING Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. United States 3D BIOPRINTING Market for Distribution Channel 1, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. United States 3D BIOPRINTING Market for Distribution Channel 2, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. United States 3D BIOPRINTING Market for Distribution Channel 3, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. United States 3D BIOPRINTING Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. United States 3D BIOPRINTING Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : United States 3D BIOPRINTING Market: Snapshot 18

TABLE NO. 2. : Drivers for the 3D BIOPRINTING Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the 3D BIOPRINTING Market: Impact Analysis 24

TABLE NO. 4. : United States 3D BIOPRINTING Market Revenue, By Material, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : United States 3D BIOPRINTING Market Revenue, By Material, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : United States 3D BIOPRINTING Market Revenue, By Material, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : United States 3D BIOPRINTING Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : United States 3D BIOPRINTING Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : United States 3D BIOPRINTING Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : United States 3D BIOPRINTING Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : United States 3D BIOPRINTING Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : United States 3D BIOPRINTING Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : United States 3D BIOPRINTING Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : United States 3D BIOPRINTING Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the U.S. 3D bioprinting Market?

The U.S. 3D bioprinting market was valued at USD 437.36 million in 2023 and is projected to reach USD 1,263.24 million by 2032, growing at a CAGR of 12.51% during the forecast period.

What factors are driving the growth of the U.S. 3D bioprinting Market?

Key drivers include the increasing prevalence of chronic diseases, an aging population, the shortage of organ donors, technological advancements in bioprinting, and growing investments in R&D, particularly in personalized medicine and regenerative medicine.

What are the key segments within the U.S. 3D bioprinting Market?

Key market segments include material types (living cells, hydrogels, extracellular matrices), applications (medical, dental, biosensors), end-users (academic institutions, pharmaceutical companies, hospitals), and technologies (inkjet-based, syringe-based, laser-based, etc.).

Who are the major players in the U.S. 3D bioprinting Market?

Major players in the U.S. 3D bioprinting market include Organovo, 3D Systems, Stratasys, Allevi, and BioBots, among others, which are leading technological innovation and application in medical research and regenerative medicine.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –